Compare · Head-to-head
Epithalon Variants vs MK-677.
Evidence, risk, regulatory flags, cost, and vendor coverage compared side by side. We don’t sell peptides — we help you choose between them.
Which should you research first?
Start with MK-677, then use the table to confirm fit.
MK-677 is the cleaner first read based on the current evidence, risk, and regulatory data stored for this pair. The right answer can still change if your goal, sport testing status, vendor constraints, or monitoring tolerance makes the other option a better fit.
Comparison next step
Personalize this head-to-head.
Take the quiz before converting a comparison into a compound, vendor, or protocol decision.
01· Subject
Epithalon Variants
Modified epithalon-like peptides marketed for anti-aging despite essentially no variant-specific human evidence.
01 · At a glance
| Decision factor | Epithalon Variants | MK-677 |
|---|---|---|
| Primary fit | longevity & anti-aging and sleep & relaxation comparisons | muscle growth & strength and longevity & anti-aging comparisons |
| Evidence | Tier D | Tier C |
| Risk | medium | med-high |
| Experience level | intermediate | advanced |
| Budget tier | mid | mid |
| Administration route | subcutaneous, intramuscular | oral |
02 · Use case & timing
| Decision factor | Epithalon Variants | MK-677 |
|---|---|---|
| Goal fit | Longevity & Anti-Aging, Sleep & Relaxation | Muscle Growth & Strength, Longevity & Anti-Aging, GH Axis Optimization |
| What users compare it for | Claims center on telomere support, sleep quality, and anti-aging signals, but evidence is largely anecdotal. | Increased GH/IGF-1 signaling, appetite rise, and potential lean-mass increase in some human studies. |
| Onset timeline | Any claimed anti-aging effect would require long follow-up and remains unproven. | GH rises acutely; IGF-1 and body-composition effects are tracked over weeks to months. |
| Main tradeoff | Evidence and product availability can still be uneven, so documentation matters more than hype. | Evidence and product availability can still be uneven, so documentation matters more than hype. |
03 · Safety & restrictions
| Decision factor | Epithalon Variants | MK-677 |
|---|---|---|
| Adverse effects | Unknown human safety; peptide modification may increase immune-reactivity or formulation risk. | Edema, increased appetite, insulin resistance, elevated fasting glucose, joint discomfort, and possible cardiovascular safety concerns. |
| Contraindications | No formal human contraindications established; avoid treating variant products as equivalent to better-studied approved therapies. | Use caution in diabetes, insulin resistance, edema-prone states, heart failure risk, and active malignancy. |
| Interaction notes | No clear interaction map; avoid assuming safety when combined with other experimental longevity agents. | Combining with other GH-axis compounds increases endocrine complexity and may worsen glucose control. |
| Regulatory status | Not approved | Not approved |
| FDA flag | FDA compounding caution | FDA compounding caution |
| WADA status | Not listed | WADA S2 |
04 · Age & monitoring
| Decision factor | Epithalon Variants | MK-677 |
|---|---|---|
| Supported age ranges | No age guidance yet | 25-34, 35-44, 45-54 |
| Life-stage note | Not yet documented | Most often discussed for younger and midlife adults, but metabolic and fluid-retention risks narrow the fit quickly with age. |
| Monitoring burden | Not specified | high |
| Follow-up cadence | Not yet documented | More frequent early follow-up, then reassessment every few months if continued. |
05 · Cost & sourcing
| Decision factor | Epithalon Variants | MK-677 |
|---|---|---|
| Typical cycle cost | No reliable estimate yet | No reliable estimate yet |
| Estimated monthly cost | No reliable estimate yet | No reliable estimate yet |
| Cost confidence | No estimate | No estimate |
06 · Before you buy
| Decision factor | Epithalon Variants | MK-677 |
|---|---|---|
| Tracked vendor listings | 0 listings | 0 listings |
| Sourcing note | No tracked product page yet, so sourcing takes more manual review. | No tracked product page yet, so sourcing takes more manual review. |
| Stack-friendly? | Usually stack-friendly | Usually stack-friendly |
Sources and review notes
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks - U.S. Food and Drug Administration - accessed 2026-05-15
Used for FDA compounding-risk context and peptide safety flags.
- The Prohibited List - World Anti-Doping Agency - accessed 2026-05-15
Used for athlete-facing WADA risk and peptide-class restrictions.
- Peptide therapeutics: current status and future directions - PubMed / Nature Reviews Drug Discovery - accessed 2026-05-15
Used for broad peptide-therapeutics background and evidence framing.
Still deciding
Get a plan tailored to you.
The quiz factors in your goal, experience, and risk tolerance to surface a starting compound and dosing range.